Summit Therapeutics (NASDAQ:SMMT) Raised to Hold at StockNews.com
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday. Several other research analysts have also recently commented on the company. The Goldman Sachs Group initiated coverage on Summit Therapeutics in ...
Publicado el: 2025-03-07 07:18:45
Autor: MarketBeat News, Fuente: etfdailynews
Compartir: 
